S2Medical
S2Medical AB (publ) is a Nasdaq-listed Swedish biomed-tech innovator specializing in wound healing, infection control, and cosmeceuticals. The company develops and sells advanced solutions like Epiprotect®, IvaQ™, Instagraft®, ADMERCIN®, and Symbiovance™ to accelerate healing, combat resistant bacteria, and enhance cosmeceuticals. With a focus on innovation, research, and a holistic approach to wound care, S2Medical aims to revolutionize treatment and reduce healthcare costs.
Industries
Nr. of Employees
small (1-50)
S2Medical
Products
Epiprotect 21x17 cm (biosynthetic cellulose dressing)
A biosynthetic cellulose film dressing supplied in a storage solution vial, intended as a protective barrier for superficial and some full‑thickness wounds; designed to adhere, permit monitoring, control moisture and reduce dressing changes.
Epiprotect Ulcer (disc-form cellulose dressing)
An 8 cm diameter biosynthetic cellulose disc intended for acute and chronic ulcer care, designed for single application, moisture control and reduced dressing changes.
Portable single-use negative pressure therapy system
A compact, single-use negative pressure wound therapy device incorporating absorbent tubing intended to promote granulation tissue formation in deep wounds while reducing dressing changes.
Antimicrobial peptide therapeutics (AMP platform)
Research-stage antimicrobial peptide compounds and formulations intended to target multi-resistant bacteria and enhance the activity of conventional antibiotics.
Instabind (optically condensed micelle fiber material)
A fiber-based material based on optically condensed micelle fibers that is durable, washable, waterproof, self-adhesive, breathable and designed to perform similarly to silk while remaining soft.
Lyophilized type I collagen sponge (distributed product)
A sterile, lyophilized type I native collagen sponge supplied for one‑time use as an active dressing to stimulate granulation, balance absorption and humidity, and act as a barrier against infection.
Epiprotect 21x17 cm (biosynthetic cellulose dressing)
A biosynthetic cellulose film dressing supplied in a storage solution vial, intended as a protective barrier for superficial and some full‑thickness wounds; designed to adhere, permit monitoring, control moisture and reduce dressing changes.
Epiprotect Ulcer (disc-form cellulose dressing)
An 8 cm diameter biosynthetic cellulose disc intended for acute and chronic ulcer care, designed for single application, moisture control and reduced dressing changes.
Portable single-use negative pressure therapy system
A compact, single-use negative pressure wound therapy device incorporating absorbent tubing intended to promote granulation tissue formation in deep wounds while reducing dressing changes.
Antimicrobial peptide therapeutics (AMP platform)
Research-stage antimicrobial peptide compounds and formulations intended to target multi-resistant bacteria and enhance the activity of conventional antibiotics.
Instabind (optically condensed micelle fiber material)
A fiber-based material based on optically condensed micelle fibers that is durable, washable, waterproof, self-adhesive, breathable and designed to perform similarly to silk while remaining soft.
Lyophilized type I collagen sponge (distributed product)
A sterile, lyophilized type I native collagen sponge supplied for one‑time use as an active dressing to stimulate granulation, balance absorption and humidity, and act as a barrier against infection.
Services
Outpatient wound clinic services including assessment, treatment using in‑house wound dressings, patient education and participation in clinical studies.
Collaborative research with universities and external researchers on biomaterials, regenerative medicine and infection control to support evidence-based product development.
Management of international distributor relationships, market registrations support and regional sales coordination to place wound-care products in local healthcare markets.
Provision of training and educational materials for clinicians on proper application and use of wound dressings, including support for emergency or conflict settings.
Outpatient wound clinic services including assessment, treatment using in‑house wound dressings, patient education and participation in clinical studies.
Collaborative research with universities and external researchers on biomaterials, regenerative medicine and infection control to support evidence-based product development.
Management of international distributor relationships, market registrations support and regional sales coordination to place wound-care products in local healthcare markets.
Provision of training and educational materials for clinicians on proper application and use of wound dressings, including support for emergency or conflict settings.
Expertise Areas
- Wound healing therapies
- Burn care
- Chronic wound management
- Biomaterials development
Key Technologies
- Biosynthetic cellulose dressings
- Lyophilized type I collagen sponges
- Portable single-use negative pressure wound therapy
- Antimicrobial peptides (AMPs)
News & Updates
S2Medical forecasts a tripling of Epiprotect sales in 2024 with continued growth targets.
S2Medical clarifies its transition to semi-annual financial reporting.
A clinical trial demonstrated that microbial cellulose treated patients had shorter hospital stays, lower pain scores, and fewer dressing changes.
A case series showing that an average of 1.7 dressings was needed until complete healing, with one application lasting 63 days.
Market Growth in Wound Care
The global wound care market reached USD 18.2 billion in 2016 and is projected to grow to USD 26.2 billion by 2023.
Regulatory Approvals
S2Medical's products based on eiratex® are CE marked and approved in multiple markets outside Europe.
S2Medical forecasts a tripling of Epiprotect sales in 2024 with continued growth targets.
S2Medical clarifies its transition to semi-annual financial reporting.
A clinical trial demonstrated that microbial cellulose treated patients had shorter hospital stays, lower pain scores, and fewer dressing changes.
A case series showing that an average of 1.7 dressings was needed until complete healing, with one application lasting 63 days.
Market Growth in Wound Care
The global wound care market reached USD 18.2 billion in 2016 and is projected to grow to USD 26.2 billion by 2023.
Regulatory Approvals
S2Medical's products based on eiratex® are CE marked and approved in multiple markets outside Europe.